Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab-stba), a ...

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions (688177.SS), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the ...

Please provide your email address to receive an email when new articles are posted on . In a video exclusive, Bruce Sands, MD, Icahn School of Medicine, reported Stelara demonstrated sustained ...

The approval is supported by evidence from adequate and well-controlled studies of Stelara. The Food and Drug Administration (FDA) has expanded the approval of Stelara ® (ustekinumab) to include ...

The approval of ustekinumab in pediatric patients was based on data from a phase 3 open-label, single-arm study (CADMUS Junior). The Food and Drug Administration (FDA) has expanded the approval of ...

BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast platform, announced an agreement with Rani to assess its Ustekinumab biosimilar (BFI-751) in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Risankizumab was noninferior to ustekinumab in clinical ...